The Guardian of Vision : Intelligent Bacteriophage-Based Eyedrops for Clinical Multidrug-Resistant Ocular Surface Infections

© 2024 Wiley‐VCH GmbH.

Bibliographische Detailangaben
Veröffentlicht in:Advanced materials (Deerfield Beach, Fla.). - 1998. - 36(2024), 38 vom: 01. Sept., Seite e2407268
1. Verfasser: Chen, Luojia (VerfasserIn)
Weitere Verfasser: Wu, Ming-Yu, Chen, Si-Ling, Hu, Rui, Wang, Yifei, Zeng, Weijuan, Feng, Shun, Ke, Min, Wang, Lianrong, Chen, Shi, Gu, Meijia
Format: Online-Aufsatz
Sprache:English
Veröffentlicht: 2024
Zugriff auf das übergeordnete Werk:Advanced materials (Deerfield Beach, Fla.)
Schlagworte:Journal Article bacterial keratitis bacteriophage eyedrops multidrug‐resistant Pseudomonas aeruginosa type I photosensitizer Ophthalmic Solutions Photosensitizing Agents
LEADER 01000caa a22002652 4500
001 NLM375784969
003 DE-627
005 20241003233136.0
007 cr uuu---uuuuu
008 240802s2024 xx |||||o 00| ||eng c
024 7 |a 10.1002/adma.202407268  |2 doi 
028 5 2 |a pubmed24n1556.xml 
035 |a (DE-627)NLM375784969 
035 |a (NLM)39091071 
040 |a DE-627  |b ger  |c DE-627  |e rakwb 
041 |a eng 
100 1 |a Chen, Luojia  |e verfasserin  |4 aut 
245 1 4 |a The Guardian of Vision  |b Intelligent Bacteriophage-Based Eyedrops for Clinical Multidrug-Resistant Ocular Surface Infections 
264 1 |c 2024 
336 |a Text  |b txt  |2 rdacontent 
337 |a ƒaComputermedien  |b c  |2 rdamedia 
338 |a ƒa Online-Ressource  |b cr  |2 rdacarrier 
500 |a Date Completed 03.10.2024 
500 |a Date Revised 03.10.2024 
500 |a published: Print-Electronic 
500 |a Citation Status MEDLINE 
520 |a © 2024 Wiley‐VCH GmbH. 
520 |a Clinical multidrug-resistant Pseudomonas aeruginosa (MDR-PA) is the leading cause of refractory bacterial keratitis (BK). However, the reported BK treatment methods lack biosecurity and bioavailability, which usually causes irreversible visual impairment and even blindness. Herein, for BK caused by clinically isolated MDR-PA infection, armed phages are modularized with the type I photosensitizer (PS) ACR-DMT, and an intelligent phage eyedrop is developed for combined phagotherapy and photodynamic therapy (PDT). These eyedrops maximize the advantages of bacteriophages and ACR-DMT, enabling more robust and specific targeting killing of MDR-PA under low oxygen-dependence, penetrating and disrupting biofilms, and efficiently preventing biofilm reformation. Altering the biofilm and immune microenvironments alleviates inflammation noninvasively, promotes corneal healing without scar formation, protects ocular tissues, restores visual function, and prevents long-term discomfort and pain. This strategy exhibits strong scalability, enables at-home treatment of ocular surface infections with great patient compliance and a favorable prognosis, and has significant potential for clinical application 
650 4 |a Journal Article 
650 4 |a bacterial keratitis 
650 4 |a bacteriophage 
650 4 |a eyedrops 
650 4 |a multidrug‐resistant Pseudomonas aeruginosa 
650 4 |a type I photosensitizer 
650 7 |a Ophthalmic Solutions  |2 NLM 
650 7 |a Photosensitizing Agents  |2 NLM 
700 1 |a Wu, Ming-Yu  |e verfasserin  |4 aut 
700 1 |a Chen, Si-Ling  |e verfasserin  |4 aut 
700 1 |a Hu, Rui  |e verfasserin  |4 aut 
700 1 |a Wang, Yifei  |e verfasserin  |4 aut 
700 1 |a Zeng, Weijuan  |e verfasserin  |4 aut 
700 1 |a Feng, Shun  |e verfasserin  |4 aut 
700 1 |a Ke, Min  |e verfasserin  |4 aut 
700 1 |a Wang, Lianrong  |e verfasserin  |4 aut 
700 1 |a Chen, Shi  |e verfasserin  |4 aut 
700 1 |a Gu, Meijia  |e verfasserin  |4 aut 
773 0 8 |i Enthalten in  |t Advanced materials (Deerfield Beach, Fla.)  |d 1998  |g 36(2024), 38 vom: 01. Sept., Seite e2407268  |w (DE-627)NLM098206397  |x 1521-4095  |7 nnns 
773 1 8 |g volume:36  |g year:2024  |g number:38  |g day:01  |g month:09  |g pages:e2407268 
856 4 0 |u http://dx.doi.org/10.1002/adma.202407268  |3 Volltext 
912 |a GBV_USEFLAG_A 
912 |a SYSFLAG_A 
912 |a GBV_NLM 
912 |a GBV_ILN_350 
951 |a AR 
952 |d 36  |j 2024  |e 38  |b 01  |c 09  |h e2407268